Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Protalix Biotherapeutics Inc (PLX) Com Stk USD0.0001

Sell:$0.22 Buy:$0.30 Change: $0.0092 (3.55%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$0.22
Buy:$0.30
Change: $0.0092 (3.55%)
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$0.22
Buy:$0.30
Change: $0.0092 (3.55%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx. Using its ProCellEx system, the Company is developing a pipeline of biosimilar or generic versions of recombinant therapeutic proteins based on its plant cell-based expression technology, which focuses pharmaceutical markets and that rely upon known biological mechanisms of action. ProCellEx protein expression system consists of a set of technologies and capabilities for the development of recombinant proteins, including advanced genetic engineering technology and plant cell-based protein expression methods. Its ProCellEx protein expression system is built on flexible custom-designed bioreactors made of polyethylene and optimized for the development of complex proteins in plant cell cultures. In June 2010, it had completed the preliminary phase I clinical trial of PRX-105.

Contact details

Address:
2 Snunit St., Science Park, POB 455
KARMIEL
20100
Israel
Telephone:
+972 (4) 9028100
Website:
www.protalix.com/
Investor relations:
Visit website

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
PLX
ISIN:
US74365A1016
Market cap:
$1.76 billion
Shares in issue:
93.50 million
Sector:
Biotechnology
Exchange:
New York Stock Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Zeev Bronfeld
    Independent Interim Chairman of the Board
  • David Aviezer
    President, Chief Executive Officer, Director
  • Yossi Maimon
    Chief Financial Officer, Vice President, Treasurer, Secretary
  • Tzvi Palash
    Chief Operating Officer
  • Yoseph Shaaltiel
    Executive Vice President - Research & Development, Director
  • Einat Almon
    Senior Vice President - Product Development
  • Sandra Lauterbach
    Vice President - Sales and Commercial Affairs

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.